United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human sCD14 ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:sCD14
  • Species:Human
Cat. No. Size Price

RHK320-01R 96 wells (1 kit) $748,87
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Urine, Milk, Plasma, Cell culture supernatant


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

1.56-100 ng/ml

Limit of Detection

1.56 ng/ml



The total assay time is 3.5 hours

The kit measures sCD14 in human Serum, Plasma, Milk, Cell culture supernatant

Assay format is 96 wells

Components of the kit are provided ready to use or concentrated

Research topic

Cell surface proteins (sCD), Immune Response, Infection and Inflammation, Immunology


CD14, the 55-kDa glycoprotein known to function as a receptor for LPS, is expressed mainly on the surface of monocytes/macrophages, and polymorphonuclear cells (PMN), the cells responsible for scavenging of LPS and bacteria. Although monocytes and PMN are the main CD14 expressing cells few reports have described CD14 expression on B-cells, mesangial cells and basophils. The plasma protein LBP plays an important role in the LPS-CD14 mediated cell activation. In addition to the function as receptor for LPS, several other functions have been ascribed to CD14; next to the recognition of micro-organisms by the innate immune system CD14 also plays a role in cell-cell interactions. Besides the membrane bound form of CD14, the soluble form of CD14 (sCD14), which lacks the GPI anchor, is also involved in LPS-induced cell activation. Two forms of sCD14 have been described. An approximately 48 kDa form, derived from monocytes membrane CD14, and a 56 kDa form, speculated to be directly released in plasma or supernatant after processing. sCD14 affects LPS functioning via several pathways. sCD14 is an intermediate in the transfer of LPS to lipoproteins, resulting into neutralization of LPS. On the contrary, sCD14 facilitates LPS activation of CD14-membrane negative cells like endo- and epithelium. Furthermore, high concentrations of sCD14 were shown to block LPS-induced activation of monocytes. sCD14 thus both enhances and reduces cellular responses to LPS.sCD14 was demonstrated to be present in plasma in levels ranging from 2 - 4 µg/ml and to be enhanced in infectious diseases.

Related Products Docs